The Supralimus-Core Sirolimus Eluting Coronary Stent System represents advanced cardiovascular technology integrating three critical components: the CE-approved Coronnium Stent pla...

The Supralimus-Core Sirolimus Eluting Coronary Stent System represents advanced cardiovascular technology integrating three critical components: the CE-approved Coronnium Stent platform, proven Sirolimus therapeutic agent, and specialized biodegradable polymers. This sophisticated combination ensures controlled drug release, optimal biocompatibility, and long-term vessel support, making it a preferred choice for interventional cardiologists worldwide. The system's design focuses on delivering consistent performance during deployment and throughout the healing process, providing medical professionals with a reliable tool for complex coronary interventions requiring precision and predictable outcomes in various clinical situations.

This stent system finds extensive application across cardiac care facilities including hospital catheterization labs, specialized cardiac centers, and emergency care units. It serves interventional cardiologists performing percutaneous coronary interventions for patients with various forms of coronary artery disease. The technology supports both elective procedures for planned revascularization and emergency interventions for acute coronary syndromes, making it versatile across different clinical settings. Medical institutions value its consistent performance in challenging cases including complex lesions and patients with multiple comorbidities requiring reliable coronary support and minimal complication rates.

The value of Supralimus-Core lies in its proven reliability and consistent performance that meets diverse clinical requirements. Healthcare providers benefit from reduced procedure times, consistent outcomes, and lower restenosis rates, which translate to better patient results and operational efficiency. The system's robust construction and quality assurance processes ensure that medical facilities can depend on predictable performance case after case, reducing the need for repeat procedures and minimizing complications. This reliability makes it a strategic investment for hospitals seeking to enhance their cardiac care services while maintaining cost-effectiveness through improved patient outcomes and reduced follow-up care requirements.

Key Features:
- CE-approved Coronnium Stent platform for proven reliability
- Sirolimus drug with strong antiproliferative properties
- Advanced blend of biodegradable hydrophobic and hydrophilic polymers
- Consistent coating thickness of 5-6 micrometers for controlled drug release
- Robust surface morphology preventing cracking, webbing, or delamination

Benefits:
- Reduced restenosis rates through controlled drug elution
- Enhanced patient safety with proven biocompatible materials
- Consistent clinical outcomes across diverse patient populations
- Reliable performance in both elective and emergency procedures
- Long-term vessel support with minimal complication risks